AstraZeneca - October 2022 - case study 1

The Christie NHS Foundation Trust (on behalf of Greater Manchester Cancer Alliance), Qure.AI Technologies Limited and AstraZeneca UK Limited are engaged in a Collaborative Working Project

Project Aims and Objectives

• The overall aim of this Collaborative Working Agreement is to collaborate to explore the value of artificial intelligence technology to aid in the detection of abnormal lung cancer nodules from chest X-ray (CXR).
• Through this Project, the Parties aim to introduce an AI technology platform to assist the radiologist in incidental pulmonary nodule (IPN) detection on chest Xray to identify lung cancer risk in seven NHS Trusts in the Greater Manchester Region.
• Clinically to demonstrate UK specific evidence for the value of AI in identifying lung nodules, including IPNs, on high volume chest x-rays done within the NHS.
• Operationally to show real world implementation of AI triage for chest x-rays for reducing missed lung cancer diagnosis.

Achievements & Milestones

• Rapid identification of CXRs with a suspicion of lung cancer to enable earlier diagnosis and activation of the diagnostic pathway by highlighting these CXRs for early review by the local radiology team
• Reduction in missed lung cancers through standardised digital assessment that may overcome human factors involved in missed diagnosis of lung cancers on CXRs
• Safety netting through standardised reporting and safety netting advice e.g. in the case of normal CXRs
• Improved efficiency of radiology time with standardised, pre-populated reporting templates.

GB-49317 October 2023